Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Literature
1.
2.
3.
Desai R, Thakkar S, Fong HK, Varma Y, Ali Khan MZ, Itare VB, Raina JS, Savani S, Damarlapally N, Doshi RP, Gangani K, Sitammagari K (2019) Rising trends in medication non-compliance and associated worsening cardiovascular and cerebrovascular outcomes among hospitalized adults across the United States. Cureus 11(8):e5389PubMedPubMedCentral
Metadata
Title
Nationwide prevalence and trends of acute cardiovascular and cerebrovascular events among adult breast cancer survivors with a history of radiation therapy
Authors
Snehal Bansod
Rupak Desai
Publication date
01-02-2020
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2020
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-020-05535-3

Other articles of this Issue 1/2020

Breast Cancer Research and Treatment 1/2020 Go to the issue

Review

Healthcare system distrust and the breast cancer continuum of care

Preclinical Study

Cytotoxic T cell depletion with increasing epithelial abnormality in women with benign breast disease

Letter to the Editor

RE: Mismatch repair protein loss in breast cancer: clinicopathological associations in a large British Columbia cohort

Preclinical study

Significance of glucocorticoid signaling in triple-negative breast cancer patients: a newly revealed interaction with androgen signaling

Clinical trial

A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer

Epidemiology

Predictors of contralateral prophylactic mastectomy in genetically high risk newly diagnosed breast cancer patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits